Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial.

Böll B, Plütschow A, Bürkle C, Atta J, Pfreundschuh M, Feuring-Buske M, Vogelhuber M, Sökler M, Eichenauer DA, Thielen I, von Tresckow B, Fuchs M, Engert A, Borchmann P; German Hodgkin Study Group (GHSG).

Br J Haematol. 2019 Apr;185(1):42-52. doi: 10.1111/bjh.15741. Epub 2018 Dec 28.

PMID:
30592027
2.

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.

Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, Herold M, Illmer T, Nilsson-Ehle H, Sökler M, Dünzinger U, Nielsen T, Launonen A, Hiddemann W.

Haematologica. 2019 Jun;104(6):1202-1208. doi: 10.3324/haematol.2018.209015. Epub 2018 Dec 20.

3.

Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.

Eichenauer DA, Plütschow A, Kreissl S, Sökler M, Hellmuth JC, Meissner J, Mathas S, Topp MS, Behringer K, Klapper W, Kuhnert G, Dietlein M, Kobe C, Fuchs M, Diehl V, Engert A, Borchmann P.

Lancet Oncol. 2017 Dec;18(12):1680-1687. doi: 10.1016/S1470-2045(17)30696-4. Epub 2017 Nov 10.

PMID:
29133014
4.

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.

Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; international group of investigators; German CLL Study Group (GCLLSG).

Lancet Oncol. 2016 Jul;17(7):928-942. doi: 10.1016/S1470-2045(16)30051-1. Epub 2016 May 20.

PMID:
27216274
5.

Volume and attenuation computed tomography measurements for interim evaluation of Hodgkin and follicular lymphoma as an additional surrogate parameter for more confident response monitoring: a pilot study.

Spira D, Sökler M, Vogel W, Löffler S, Spira SM, Brodoefel H, Fenchel M, Horger M.

Cancer Imaging. 2011 Oct 31;11:155-62. doi: 10.1102/1470-7330.2011.0022.

6.

Size and attenuation CT (SACT) of residual masses in patients with follicular non-Hodgkin lymphoma: more than a status quo?

Spira D, Vogel W, Sökler M, Löffler S, Sauter A, Schulze M, Horger M.

Eur J Radiol. 2012 Jul;81(7):1657-61. doi: 10.1016/j.ejrad.2011.03.035. Epub 2011 Apr 2.

PMID:
21459529
7.

Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V.

N Engl J Med. 2010 Aug 12;363(7):640-52. doi: 10.1056/NEJMoa1000067.

8.

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

J Clin Oncol. 2010 May 1;28(13):2239-45. doi: 10.1200/JCO.2009.25.1835. Epub 2010 Apr 5.

PMID:
20368566
9.

[Systemic mastocytosis].

Sökler M, Kanz L.

Dtsch Med Wochenschr. 2005 Oct 28;Suppl 1:96. German. No abstract available.

PMID:
16379260
10.

[Systemic mastocytosis].

Sökler M, Kanz L.

Dtsch Med Wochenschr. 2005 Mar 4;130(9):474. German. No abstract available.

PMID:
15731964
11.

Sustained complete remission of recurrent acute myeloid leukaemia with a single dose of gemtuzumab ozogamicin and low-dose interleukin-2 maintenance.

Radsak MP, Salih HR, Sökler M, Kanz L, Denzlinger C.

Leukemia. 2002 Sep;16(9):1870-1. No abstract available.

12.

Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma.

Dittmann H, Sokler M, Kollmannsberger C, Dohmen BM, Baumann C, Kopp A, Bares R, Claussen CD, Kanz L, Bokemeyer C.

Oncol Rep. 2001 Nov-Dec;8(6):1393-9.

PMID:
11605073
13.

Noninvasive procedures for diagnosis of renovascular hypertension in renal transplant recipients--a prospective analysis.

Erley CM, Duda SH, Wakat JP, Sökler M, Reuland P, Müller-Schauenburg W, Schareck W, Lauchart W, Risler T.

Transplantation. 1992 Nov;54(5):863-7.

PMID:
1440854

Supplemental Content

Loading ...
Support Center